☰

Nataliya V. Uboha, Ph.D. - Publications

Affiliations: 
2006 Yale University, New Haven, CT 
Area:
Molecular Neurobiology, Molecular basis of behavior
Tree Info Grants Similar researchers PubMed Report error

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Patel MA, Kratz JD, Lubner SJ, Loconte NK, Uboha NV. Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102500. PMID 35839430 DOI: 10.1200/JCO.21.02500  0.389
2021 Patel M, Uboha NV. Treatment Approach to Adenocarcinoma of the Ampulla of Vater. Current Treatment Options in Oncology. 22: 103. PMID 34586537 DOI: 10.1007/s11864-021-00894-5  0.396
2020 Uboha NV, Lubner SJ, LoConte NK, Mulkerin DL, Eickhoff JC, Deming DA. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Investigational New Drugs. PMID 32253554 DOI: 10.1007/S10637-020-00929-Y  0.728
2020 Dhakras P, Uboha N, Horner V, Reinig E, Matkowskyj KA. Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma Translational Gastroenterology and Hepatology. 5: 55-55. DOI: 10.21037/Tgh.2020.01.08  0.673
2020 Uboha NV, Eickhoff JC, Chandrasekharan C, Jalal SI, Benson AB, Deming DA, Lindemann S, Hochster HS. Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149. Journal of Clinical Oncology. 38: TPS461-TPS461. DOI: 10.1200/Jco.2020.38.4_Suppl.Tps461  0.753
2020 Uboha NV, Lubner SJ, LoConte NK, Mulkerin D, Eickhoff JC, Deming DA. Phase I dose-escalation trial of trifluridine/tipiracil (TAS-102) and temozolomide in the treatment of advanced neuroendocrine tumors. Journal of Clinical Oncology. 38: 615-615. DOI: 10.1200/Jco.2020.38.4_Suppl.615  0.734
2020 Kratz JD, Gillette A, Rehman S, Sunil A, Johnson KA, Pasch C, Lemmon K, Lassen N, Abbott DE, Carchman E, Foley EF, Heise C, Lawson EH, LoConte NK, Lubner SJ, ... Uboha NV, et al. Defining population response of patient-derived colorectal cancer organoids against prospective clinical outcomes. Journal of Clinical Oncology. 38: 177-177. DOI: 10.1200/Jco.2020.38.4_Suppl.177  0.727
2020 Goyal L, Lamarca A, Strickler JH, Cecchini M, Ahn DH, Baiev I, Boileve A, Tazdait M, Hannan LM, Jia J, Marble HD, Barzi A, Sahai V, Lennerz JK, Kelley RK, ... Uboha NV, et al. The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). Journal of Clinical Oncology. 38: e16686-e16686. DOI: 10.1200/Jco.2020.38.15_Suppl.E16686  0.738
2020 Kratz JD, LoConte NK, Lubner SJ, Mulkerin D, Uboha NV, Deming DA. Efficacy of single-agent epidermal growth factor receptor inhibition in the second-line setting for metastatic colorectal cancer with a goal towards retreatment strategies. Journal of Clinical Oncology. 38: e16035-e16035. DOI: 10.1200/jco.2020.38.15_suppl.e16035  0.734
2020 Boni V, Burris III HA, Liu JF, Spira AI, Arkenau H, Fidler MJ, Rosen LS, Sweis RF, Uboha NV, Sanborn RE, O'Neil B, Harding JJ, LoRusso P, Weise AM, Garcia-Corbacho J, et al. CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC). Journal of Clinical Oncology. 38: 526-526. DOI: 10.1200/Jco.2020.38.15_Suppl.526  0.755
2020 Deming DA, Emmerich P, Turk AA, Lubner SJ, Uboha NV, LoConte NK, Mulkerin D, Kim DH, Matkowskyj KA, Weber SM, Abbott D, Eickhoff JC, Bassetti MF. Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC). Journal of Clinical Oncology. 38: 4046-4046. DOI: 10.1200/Jco.2020.38.15_Suppl.4046  0.745
2020 Emmerich P, Matkowskyj KA, McGregor S, Kraus S, Bischel K, Qyli T, Buehler D, Pasch C, Babiarz C, Depke M, Clipson L, Wisinski KB, Burkard ME, Baschnagel A, Uboha NV, et al. VCAN accumulation and proteolysis as predictors of T lymphocyte-excluded and permissive tumor microenvironments. Journal of Clinical Oncology. 38: 3127-3127. DOI: 10.1200/Jco.2020.38.15_Suppl.3127  0.724
2020 Thistlethwaite F, Naing A, Gil-Martin M, LoRusso P, Randhawa M, Eskens F, Sanborn RE, Uboha NV, Cho DC, Spira AI, Bondarenko I, Plummer ER, Garcia-Corbacho J, Victoria I, Lavernia J, et al. PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab. Journal of Clinical Oncology. 38: 3005-3005. DOI: 10.1200/Jco.2020.38.15_Suppl.3005  0.756
2020 Kratz JD, Sunil A, Conroy M, Pasch CA, Lassen N, Houtler H, Lemmon KK, Clipson L, Abbott DE, Carchman EH, Lawson EH, Loconte NK, Lubner SJ, Matkowskyj KA, Mulkerin DL, ... Uboha N, et al. Abstract 2701: Patient-derived colorectal cancer organoid therapeutic escalation: Tracking resistance to EGFR inhibition for predicting therapeutic sensitivity Tumor Biology. DOI: 10.1158/1538-7445.Am2020-2701  0.347
2019 Furuse J, Goyal L, Bahleda R, Valle J, Moehler M, Oh D, Chang H, Kelley RK, Javle M, Borad M, Chen L, Uboha N, Klümpen H, O’Dwyer PJ, Li D, et al. AB040. P-08. FOENIX-CCA2: a phase 2 study of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements Hepatobiliary Surgery and Nutrition. 8: AB040-AB040. DOI: 10.21037/Hbsn.2019.Ab040  0.673
2019 Goyal L, Bahleda R, Furuse J, Valle JW, Moehler MH, Oh D, Chang H, Kelley RK, Javle MM, Borad MJ, Chen L, Uboha NV, Klumpen H, O'Dwyer PJ, Li D, et al. FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Journal of Clinical Oncology. 37: TPS468-TPS468. DOI: 10.1200/JCO.2019.37.4_suppl.TPS468  0.75
2019 Uboha NV, Maloney JD, McCarthy D, Deming DA, LoConte NK, Matkowskyj K, Eickhoff JC, Mulkerin D, DeCamp MM, Lubner SJ, Turk AA, Bassetti MF. Phase I/II trial of perioperative avelumab in combination with chemoradiation in the treatment of stage II/III resectable esophageal cancer. Journal of Clinical Oncology. 37: TPS181-TPS181. DOI: 10.1200/Jco.2019.37.4_Suppl.Tps181  0.755
2019 Turk AA, Lubner SJ, Uboha NV, LoConte NK, Mulkerin D, Kim DH, Matkowskyj K, Weber SM, Abbott D, Eickhoff JC, Bassetti MF, Deming DA. A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 37: 680-680. DOI: 10.1200/Jco.2019.37.4_Suppl.680  0.741
2019 Kratz JD, Uboha NV, LoConte NK, Lubner SJ, Mulkerin D, Matkowskyj K, Turk AA, Sprackling CM, Eickhoff JC, Deming DA. Utility of effect size to define populations with durable clinical outcomes across trials of metastatic colorectal cancer. Journal of Clinical Oncology. 37: e15104-e15104. DOI: 10.1200/Jco.2019.37.15_Suppl.E15104  0.711
2019 Bassetti MF, Turk AA, Lubner SJ, Uboha NV, LoConte NK, Mulkerin D, Kim DH, Matkowskyj K, Weber SM, Abbott D, Eickhoff JC, Deming DA. A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic MSS colorectal cancer (CRC): A postoperative safety analysis. Journal of Clinical Oncology. 37: e15047-e15047. DOI: 10.1200/Jco.2019.37.15_Suppl.E15047  0.744
2019 Uboha NV, Maloney JD, McCarthy D, Deming DA, LoConte NK, Matkowskyj K, Eickhoff JC, Emmerich P, DeCamp MM, Lubner SJ, Turk AA, Bassetti MF. Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer. Journal of Clinical Oncology. 37: 4041-4041. DOI: 10.1200/Jco.2019.37.15_Suppl.4041  0.742
2019 Uboha NV, Milhem MM, Kovacs C, Amin A, Magley A, Purkayastha DD, Piha-Paul SA. Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies. Journal of Clinical Oncology. 37: 2553-2553. DOI: 10.1200/JCO.2019.37.15_SUPPL.2553  0.753
2019 Naing A, Thistlethwaite FC, Spira AI, Garcia-Corbacho J, Randhawa M, Eskens F, O'Neil B, Lavernia J, Uboha NV, Hamid O, El-Khoueiry AB, Benson BA, Garner W, Huels VJ, Arkenau H, et al. CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072. Journal of Clinical Oncology. 37: 2513-2513. DOI: 10.1200/JCO.2019.37.15_SUPPL.2513  0.73
2018 Kratz JD, Uboha NV, Lubner SJ, Mulkerin DL, Clipson L, Yi Y, Yu M, Matkowskyj KA, LoConte NK, Deming DA. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 1442-1450. PMID 30545991 DOI: 10.6004/Jnccn.2018.7074  0.753
2018 Deming DA, Kim DH, Matkowskyj K, Uboha NV, Lubner SJ, LoConte NK, Mulkerin D, Abbott D, Weber SM, Winslow E, Jeraj R, Ritter MA, Perlman S, Eickhoff JC, Bassetti MF. Keynote 290: Pembrolizumab (pem) in combination with stereotactic body radiotherapy for resectable liver metastatic colorectal cancer. Journal of Clinical Oncology. 36: TPS874-TPS874. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps874  0.749
2018 Uboha NV, Deming DA, Lubner SJ, Mulkerin D, Eickhoff JC, LoConte NK. Safety of trifluridine/tipiracil (TAS-102) in combination with temozolomide for metastatic neuroendocrine tumors. Journal of Clinical Oncology. 36: TPS549-TPS549. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps549  0.746
2018 Kratz JD, LoConte NK, Lubner SJ, Mulkerin D, Uboha NV, Deming DA. Tumor bulk to predict clinical outcomes of anti-EGFR therapy in treatment refractory metastatic colorectal cancer independent of sidedness. Journal of Clinical Oncology. 36: 795-795. DOI: 10.1200/Jco.2018.36.4_Suppl.795  0.75
2018 Stein S, Uboha NV, Dooley K, Hochster HS. A pilot study of omalizumab to reduce the incidence of oxaliplatin-induced hypersensitivity reaction (HSR): An interim analysis. Journal of Clinical Oncology. 36: e15555-e15555. DOI: 10.1200/jco.2018.36.15_suppl.e15555  0.629
2018 Sanborn RE, Menke CW, Autio KA, Arkenau H, Corbacho JG, LoRusso P, Plummer ER, Uboha NV, Freeman ML, Wydmanski J, Huels V, Zheng B, Will M, Humphrey RW, Thistlethwaite F, et al. Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 36: 3072-3072. DOI: 10.1200/jco.2018.36.15_suppl.3072  0.724
2018 Autio KA, Arkenau H, O'Neil BH, Bendell JC, El-Khoueiry A, Strauss J, Weise A, Uboha NV, Rizvi NA, Zheng B, Desnoyers L, Stroh M, Carman L, Humphrey RW, Will M, et al. Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 36: 3071-3071. DOI: 10.1200/JCO.2018.36.15_SUPPL.3071  0.721
2017 Burkard ME, Deming DA, Parsons BM, Kenny PA, Schuh MR, Leal T, Uboha N, Lang JM, Thompson MA, Warren R, Bauman J, Mably MS, Laffin J, Paschal CR, Lager AM, et al. Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. Jco Precision Oncology. 1. PMID 32913980 DOI: 10.1200/PO.16.00022  0.682
2017 Lubner SJ, Uboha NV, Deming DA. Primary and acquired resistance to biologic therapies in gastrointestinal cancers. Journal of Gastrointestinal Oncology. 8: 499-512. PMID 28736637 DOI: 10.21037/jgo.2017.01.16  0.705
2017 Kratz JD, LoConte NK, Lubner SJ, Mulkerin D, Matkowskyj K, Uboha NV, Lubner MG, Kim DH, Pickhardt PJ, Deming DA. Tumor bulk as an independent marker of anti-EGFR therapeutic benefit in metastatic colorectal cancer. Journal of Clinical Oncology. 35: e15054-e15054. DOI: 10.1200/jco.2017.35.15_suppl.e15054  0.739
2015 Uboha N, Hochster HS. TAS-102: a novel antimetabolite for the 21st century. Future Oncology (London, England). 12: 153-63. PMID 26616466 DOI: 10.2217/fon.15.276  0.71
2015 Deming D, Uboha N, Zafar SY, Rosenberg S, Bassetti M, Glasgow S, Borden EC, Lubner S. Adjuvant Chemotherapy for Stage II Rectal Cancer. Seminars in Oncology. 42: e99-e107. PMID 26615141 DOI: 10.1053/J.Seminoncol.2015.09.033  0.695
2007 Uboha NV, Flajolet M, Nairn AC, Picciotto MR. A calcium- and calmodulin-dependent kinase Ialpha/microtubule affinity regulating kinase 2 signaling cascade mediates calcium-dependent neurite outgrowth. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 4413-23. PMID 17442826 DOI: 10.1523/Jneurosci.0725-07.2007  0.702
2006 Cleary MA, Uboha N, Picciotto MR, Beech RD. Expression of ezrin in glial tubes in the adult subventricular zone and rostral migratory stream. Neuroscience. 143: 851-61. PMID 16996217 DOI: 10.1016/J.Neuroscience.2006.08.028  0.726
2004 Stedman DR, Uboha NV, Stedman TT, Nairn AC, Picciotto MR. Cytoplasmic localization of calcium/calmodulin-dependent protein kinase I-alpha depends on a nuclear export signal in its regulatory domain. Febs Letters. 566: 275-80. PMID 15147908 DOI: 10.1016/J.Febslet.2004.04.042  0.696
Show low-probability matches.